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Adeno-associated virus (AAV) is generally considered to be an attractive vector for 
gene delivery. Previous attempts to transduce auditory hair cells and support cells with 
AAV have not been successful. New AAV serotypes are now available that have not yet 
been tested in the auditory system. These vectors are able to target a wide range o f cells, 
and in some cases, may use different cell surface receptors and co-receptors for viral 
entry into cells. For example, AAV2 has been shown to bind heparan sulfate 
proteoglycans with alpha2betaV integrin and fibroblast growth factor receptor 1 as a co­
receptor. AAV5 binds sialic acid and uses platelet derived growth factor as a co-receptor. 
To assess the transduction efficiency o f AAV in specific cell types within the cochlea, 
primary cochlear explants from CDi mice age PO-1 were transduced with AAV serotypes 
1, 2 or 5 carrying the GFP gene expression cassette. GFP gene expression was detected 
in hair cells and support cells following transduction with AAVl and AAV2 when the 
ubiquitous CAG promoter. AAV5 transduced fibroblasts, neurons, and few support cells 
within the cochlear explants but not sensory epithelial cells. To determine whether 
support cell specific expression would occur, primary cochlear explants were treated with 
A A V l, 2, or 5 carrying the GFP gene driven by the astrocyte-specific GFAP promoter. 
Under these conditions, GFP expression was observed specifically in support cells but 
not hair cells following transduction with AAVl and AAV2. No GLAST positive cells 
showed GFP expression follovmig transduction with AAVl or AAV5. However, GFP 
expression was observed within cell bodies o f GLAST positive cells following 
transduction with AAV2. A gradient o f GFP expression was observed in a basal to apical 
preference for each serotype with both promoters. When the GFP marker gene was driven 
by the CAG promoter, robust expression in hair cells was observed following 
transduction o f primary mouse cochlear explants with AAVl and AAV2. However, 
AAV5 transduced hair cells and support cells inefficiently. Using AAVl and AAV2, we 
further demonstrated that GFP gene expression could be directed specifically to support 
cells using the GFAP promoter.
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Introduction
Auditory System
In mammals, the cochlea is the sensory end organ of the auditory system. The 
cochlea is encased in a bony structure called the otic capsule (Figure 1). It is located in 
the inner ear and forms a coiled cavity of two to four turns in most species. The basal 
end tranduces high frequency sounds while the apex tranduces low frequencies. The 
organ of Corti is the sensory organ of the cochlea. It sits on the basilar membrane and is 
covered by the Vestibular (or Reissner’s) membrane. This forms the scala media, a fluid- 
filled compartment containing endolymph. Endolymph is similar to intracellular fluids 
containing a high concentration o f potassium (Raphael 2003). The two adjacent 
compartments are the scala vestibuli above and the scala tympani below, both of which 
contain perilymph. Perilymph is similar to extracellular fluid, high in sodium, and is 
continuous with cerebral spinal fluid (CSF) via the cochlear aqueduct (Raphael 2003).
Hair cells and support cells are the predominant cell types within the organ of 
Corti and exhibit a distinct architectural organization (see Figure 1). Hair cells, named 
for the bundles o f stereocillia at their apical ends, are divided into two distinct 
populations based on their location within the organ of Corti. The inner hair cells form a 
single row and are the primary sensory cells o f the cochlea. The three rows o f outer hair 
cells amplify the mechanical activity of the basilar membrane and increase sensitivity to 
sound. Inner hair cells are innervated by a single type I neuron, while the outer hair cells 
are innervated by 5-100 type II neurons (Raphael 2003; Squire LR 2003). The inner hair 
cells are considered to transduce the initial, rapid response to sound and outer hair cells 
magnify and fine-tune the signal.
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Support cells are a population of highly differentiated epithelial cells located 
immediately beneath the hair cells and rest on the basilar membrane (Ashmore 2000; 
Rubel 2002; Raphael 2003). There are several types of support cells based on 
morphology and location within the organ of Corti including; Interdental, Pillar, Dieters’, 
and Hensen cells. The function of mammalian support cells is unclear but they may be 
involved in the homeostasis o f the ionic environment and stiffness o f the cochlear 
partition (Raphael 2003).
In avian systems, a population of support cells can differentiate into hair cells 
after noise or aminoglycoside antibiotic damage (Rubel 1991; Cotanche 1997; Ishimoto 
2002). After damage to the sensory epithelia, specific support cells that are in direct 
contact to the damaged hair cells are induced to return to the cell cycle and divide 
(Cotanche 1997). Contanche (1997) demonstrated that bromodeoxyuridine (BrdU) 
labeled support cells could give rise to numerous daughter cells that could become either 
hair cells or support cells (Cotanche 1997). These new hair cells were found to develop 
stereocillia and form functional neuronal connections. However, hair cells have not been 
observed to spontaneously regenerate in mammals.
Figure 1. Cochlea.
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Figure 1. Cochlea.
A schematic illustration o f the mammalian inner ear. The different regions and cell types 
are labeled, (a) Cochlea and vestibular region o f inner ear. (b) Cross section of the 
cochlea, (c) Scala media, (d) Single inner hair cell. These images have been reproduced 
from The Essentials o f  Human Anatomy and Physiology 3'̂ '̂  Ed. McGraw Hill 2000.
Hearing loss
More than 20 million Americans suffer from some type of hearing loss (Kho 
2000; Luebke 2001). There are five major causes of hearing loss (Kotecha 1994; Wersall 
1995; Hudspeth 2000). First, infections such as meningitis and rubella, have been shown 
to cause severe hearing loss by and can cause inflammation leading to damage of the 
sensory epithelia (Lai 2002). Second, acute acoustic trauma which can occurs after 
exposure to loud sound. The mechanism for this type of damage is mediated in part by 
glutamate excitotoxicity. Third, gradual deterioration from chronic exposure to a loud 
sound or the breakdown of small blood vessels due to atherogenesis (Hudspeth 2000).
The fourth major cause of hearing loss is due to drug-related ototoxicity.
Aminoglycoside antibiotics are charged, poly-cationic molecules which include 
gentamicin and streptomycin (Kotecha 1994). These antibiotics are known to be both 
ototoxic and nephrotoxic. Aminoglycoside antibiotics cause hair cell death in the cochlea 
and vestibular regions with the most basal regions affected first (Wersall 1995). 
Gentamicin is widely used to treat Gram-negative bacterial infections. The damage 
induced by gentamicin toxicity results in lesions o f the outer hair cells leading to the 
ultimate destruction of those cells (Kotecha 1994). Another class of drugs with ototoxic 
side effects is platinum-based chemotherapeutics. These drugs are used to treat solid and 
disseminated forms of cancer (McFadden 2003). An example of this class o f drugs is 
Cisplatin, which is known to be ototoxic, neurotoxic and nephrotoxic. The side effects of 
cisplatin include irreversible bi-lateral sensorineural hearing loss and tinnitus (ringing in 
the ear) (Sergi 2003). Cisplatin-induced otoxicity is observed at the high frequency 
regions o f the cochlea and is dose-dependent. Damage involves destruction of outer hair
cells and sporadic loss o f inner hair cells. Degeneration of the stria vascularis and a 
significant decrease in spiral ganglion cells has also been reported (Sergi 2003).
The last major cause of hearing loss is due to genetic disease. There are more 
than 100 genetically-based hearing disorders. Two of the most common are Usher’s 
syndrome and mutations in the connexin 26 gene. Usher’s syndrome, an example of 
syndromic hearing loss, features deafness and vestibular dysfunction along with 
blindness (Steel 1997; Hone 2003). This syndrome affects 4.4 per 100,000 people in the 
US and accounts for 2-4% of profound deafness and 50% of the deaf-blind population 
(Nance 2003). Non-syndromic hearing loss makes up 70-80% of genetic deafness 
(Nance 2003). Mutations in the connexin 26 gene lead to the most prevalent form of non- 
syndromic hearing loss (Avraham 2003). This is responsible for up to half of autosomal- 
recessive non-syndromic hearing loss and a significant amount of sporadic hearing loss 
with mutations identified in over 60 different loci (Hone 2003).
Gene Therapy
Current treatments such as hearing aids and cochlear implants are not always 
available or useful for people with inherited or acquired hearing disorders. These 
treatments use the remaining functioning part o f the auditory system to correct or 
enhance hearing for patients that have previously had normal or slightly less than normal 
hearing. The lack o f effective treatment has prompted interest in the potential application 
o f newly emerging gene transfer methods that may provide an additional option for the 
treatment o f hearing loss. The compartmentalization of the inner ear is ideal for localized 
gene therapy treatments. The fluid-filled compartments allow secreted gene products to
diffuse throughout the cochlea making them available to all cell types. Most mammals 
have a cochlear aqueduct that connects directly to the cerebral spinal fluid. However, 
most humans don’t have a cochlear aqueduct, making the inner ear a closed system and 
thus limiting dissemination of introduced therapeutic genes to unwanted tissues outside 
o f the cochlea itself (Van de Water 1999).
Gene transfer, or gene therapy, can be defined as the transfer o f nucleic acids for 
the treatment or prevention of disease. The objective o f gene transfer is to replace a 
defective gene with a correct, exogenous copy or to deliver a therapeutic gene. The ideal 
vehicle for gene therapy would: 1) be easily produced and purified, 2) be non- 
immunogenic and non-oncogenic, 3) allow unlimited gene packaging capacity, 4) be 
tissue or cell type-specific, 5) have prolonged, controllable expression, and 6) the ability 
to transfect both dividing and non-dividing cells (Staecker 2001; Grimm 2002; Lu 2004). 
Methods o f gene transfer include non-viral vectors and a variety of viral vectors (Robbins
1998). So far, none of these methods meets the criteria as the “ideal” gene transfer 
vehicle. However, each has their share of advantages and disadvantages.
Non-viral Vectors
Naked nucleic acids (DNA) can be directly delivered to cells in several ways. 
Electroporation uses an electric current to force DNA into cells. This method can 
damage or kill large numbers o f cells and may not be practical for in vivo use. DNA can 
also be delivered to cells using a “gene gun” . This method uses a helium driven gun to 
“shoot” gold-plated beads covered with DNA into cells (Robbins 1998). However, using 
these methods, the efficiency and duration of expression is highly variable. Finally, the
direct addition o f “naked” nucleic acids is limited by permissive cell types, such as 
muscle, and has a short duration of expression (Robbins 1998; Poulsen 2002).
Liposomes are positively charged molecules that can be treated to form pseudo­
membranes. The advantages o f liposomes are that they are non-infectious, easy to make, 
and have a virtually unlimited packaging capacity. However, they have been shown to be 
relatively inefficient in gene transfer and associated with a short duration of transgene 
expression (approximately 1 week) (Van de Water 1999; Poulsen 2002). Another major 
disadvantage is there is almost no tissue-targeting capability. Jero et al. (2001) used 
gelfoam soaked with a liposome-GFP plasmid complex to deliver GFP to the mouse 
cochlea via round window application. Increased GFP expression was observed in the 
ipsilateral cochlea specifically within the spiral limbus, spiral ganglion cells and 
Reissner’s membrane (Jero 2001).
Viral Vectors for Gene Therapy
Viral mediated gene delivery, or transduction, is a highly efficient means of gene 
transfer. However, there are several factors that affect gene expression including gene 
size and maintenance, immune response, and promoter selection. Gene size is an 
important consideration and the packaging capacities o f viral vectors differ greatly. 
Therapeutic genes for hearing loss, or any disease, are highly variable in size, therefore 
the gene therapy vector needs to be flexible in its packaging capacity. For example, 
adeno-associated virus (AAV) has a relatively small packaging size (4.5kb) compared to 
herpes simplex virus (HSV) with a relatively large capacity (50kb).
How the transgenes are maintained has a large impact on the duration of gene 
expression. This depends in part on the viral vector used. Genes can integrate randomly, 
in a site-specific manner into the host cell chromosome, or can be maintained episomally 
within the nucleus. Random integration into the host chromosome can cause gene 
disruption and/or oncogenic transformation of the transduced cell. Both of which are 
undesirable and could cause the ultimate destruction of the transduced cell or 
uncontrolled cell proliferation. However, chromosomal integration can lead to permanent 
transduction of a cell and subsequent maintenance after cell division.
The ability o f the virus to elicit an immune response also determines the duration 
o f gene expression. The viral proteins and/or the antigenicity o f the transgene itself can 
play a role in the potential immune response. This could be considered a beneficial effect 
in the case of gene transfer for cancer treatment. If  the vector is targeted to cancer cells, 
the immune system may then recognize the cancerous cells as foreign thus mounting an 
immune response against the tumor itself. However, if long-term expression is the goal, 
an immune response could decrease the duration of expression by the ultimate 
elimination o f the transduced cells. An immune response could also inhibit the ability to 
re-administer the vector if multiple doses are required.
The promoter selected can determine which cell type(s) express the transduced 
gene and the level of expression. Traditionally, the human cytomegalovirus immediate 
early promoter (CMV) has been the promoter of choice for most gene transfer studies. It 
is a ubiquitous, constitutive promoter that has been shown to drive very high levels of 
gene expression. The CAG promoter is a hybrid promoter of the chicken beta-actin 
(CBA) and CMV promoters (Xu 2001; Klein 2002). This is a ubiquitous promoter and
has been shown to drive robust expression in liver and brain (Xu 2001; Klein 2002). The 
glial fibrillary acidic protein (GFAP) promoter drives expression in a more selective 
subset o f glial cells with an astrocytic phenotype (Rio 2002). Thus, promoter selection is 
one way o f targeting tissue or cells of interest and minimizing possible complications o f 
nonspecific transduction.
Regulatory elements are sequences within the DNA that control transcription, 
either negatively or positively, by binding to a particular site(s) on the DNA. An 
example o f an enhancer regulatory element is the woodchuck hepatitis virus post- 
transcriptional regulatory element (WPRE). This gene has evolved to stimulate the 
expression o f intronless viral messages by aiding in transport out o f the nucleus (Loeb 
1999). WPRE has been shown to increase the stability and level o f gene expression, both 
in vitro and in vivo (Loeb 1999; Klein 2002).
There are many viral vectors available for use in gene transfer. These include 
retrovirus, HSV, adenovirus and AAV. As with non-viral vectors these too have both 
pros and cons for use as gene therapy vectors.
Retrovirus
Retroviruses, including lentivirus murine leukemia virus, contain a single­
stranded RNA genome (Bems 1991; Robbins 1998). These viral vectors have a 
packaging capacity of 6-8kb (Poulsen 2002). Unlike most retroviruses, lentivirus can 
transduce both mitotic and post-mitotic cells. This class of vectors is relatively easy to 
produce in moderate titers (Robbins 1998). Both the advantages and disadvantages o f 
retroviral vectors stem from their ability to integrate into the host chromosome. The
10
advantages o f integration include expression of the transgene for the life of the cell and 
maintenance o f that gene after mitotic divisions (Robbins 1998). The major drawback of 
this is the possibility of disrupting a functional gene or oncogenic transformation of the 
transduced cell after random integration (Berns 1991; Van de Water 1999; Poulsen 
2002). Lentivirus has been shown to transduce cells within the inner ear. However, 
transduction was restricted to the perilymphatic space (Han 1999).
Herpes simplex virus
Herpes simplex virus type I (HSV) is a large double-stranded DNA virus with a 
genome o f approximately 150kb. As a viral vector, HSV has a packaging capacity of 
approximately 50kb and preferentially targets neuronal derived tissue (Van de Water
1999). The main disadvantage of HSV as a vector is the possibility of the virus entering 
into a lytic versus a latent life cycle. In the lytic cycle, large quantities of the virus are 
produced and the transduced cell is ultimately destroyed by the host immune system (Van 
de Water 1999). However, modifications have been made rendering HSV vectors 
replication deficient. Thus, recombinant HSV vectors enter only the latent stage and 
evade the host immune system (Robbins 1998; Van de Water 1999). A major 
disadvantage of HSV is the associated short duration of transgene expression, often less 
than two months. Another disadvantage is the relative difficulty in production of high 
titers thus a larger volume of virus must be used compared to other viral vectors 
(Staecker 2001). This virus has been used extensively in gene transfer studies in the 
mammalian nervous system and auditory system (Derby 1999). When HSV was injected 
into the round window of the guinea pig, cells in the spiral ligament, Reissner’s
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membrane, scala vestibuli, and some support cells within the organ o f Corti were 
transduced (Kawamoto 2001). However, expression decreased to undetectable levels in 
only 6 days (Derby 1999).
Adenovirus
Adenovirus is a double-stranded DNA virus with a genome of 36 kb in length 
(Lai 2002). Adenoviral vectors accommodate relatively large inserts (8-lOkb) and 
mediate high levels o f transient protein expression (Van de Water 1999; Lai 2002; Li 
Duan 2002). These vectors have been shown to transduce a broad range of both mitotic 
and post-mitotic host cells. Transduced genes are maintained episomally (Lai 2002; Li 
Duan 2002). A major drawback in using adenoviral vectors is the fact that they introduce 
viral genes into the host cell that can stimulate an immune response. This limits the 
duration o f gene expression due to the ultimate destruction of the transduced cells as well 
as prohibiting re-administration of the viral vector (Robbins 1998; Van de Water 1999; 
Lai 2002).
Adenovirus has been used extensively for gene transfer studies in many systems, 
including the auditory system, and has been shown to transduce cells within the cochlea 
o f mouse and guinea pig (Stover 2000; Kawamoto 2001; Ishimoto 2002; Kanzaki 2002; 
Kawamoto 2003). Adenovirus has been shown to transduce the scala tympani of the 
basal and second turn, over 90% of inner hair cells, and more than 50% of outer hair cells 
and some supporting cells of the guinea pig in vivo. (Stover 2000; Luebke 2001; Luebke
2001). Adenovirus containing glial-derived neurotrophic factor (GDNF) has been shown 
to protect hair cells against sound damage (Kawamoto 2001). Ishimoto et al. (2002)
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showed gene transfer into supporting cells o f guinea pig using adenovirus. The results 
revealed damage to the hair cells when adenovirus was directly injected into the scala 
media. However, using immunostaining, it was shown that all supporting cells within the 
organ o f Corti and cells in the inner and outer sulcus were positive for the transgene 
(Ishimoto 2002).
Adeno-associated Virus
Adeno-associated virus (AAV) is a single-stranded DNA virus from the family 
Parvoviridae and genus dependovirus (Tal 2000; Smith-Arica 2001; Rabinowitz 2002; 
Xie 2002). The genome of AAV is approximately 4700 nucleotides in length (Tal 2000; 
Sanlioglu 2001; Lai 2002; Monahan 2002). AAV has many properties that make it an 
attractive viral vector for gene transfer. Although approximately 85% of humans are 
seropositive, the virus has not been associated with any pathology or disease (Lalwani 
1998; Carter 2000; Stover 2000; Lai 2002; Xie 2002; Tenenbaum 2003). One of the most 
appealing qualities is its ability to transduce a wide range of both mitotic and post-mitotic 
cells (Lalwani 1998; Tal 2000; Sanlioglu 2001; Smith-Arica 2001; Lai 2002). The 
majority o f the AAV viral genome (96%) has been removed from the current 
recombinant AAV vectors (rAAV). Only the 145bp inverted terminal repeats (ITR) are 
retained and are the minimal sequence required for packaging (Carter 2000; Monahan 
2002). Because of this fact, transduced cells do not produce AAV antigens (Smith-Arica 
2001; Monahan 2002). This limits the immune response to transduced cells and allows 
transgene expression to persist for up to at least 5 years (Stover 2000; Lai 2002; Monahan
2002). However, neutralizing antibodies have been generated against the capsid protein
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of AAV serotype 2 and immune response to specific gene products has been observed 
(Monahan 2002; Tenenbaum 2003). Clinical trials using AAV are currently underway 
for treatment o f cystic fibrosis, hemophilia B, and limb girdle muscular dystrophy 
(Monahan 2002; Xie 2002; Tenenbaum 2003). These clinical trials have found no 
apparent pathological effects on cell growth and differentiation.
Currently, there are eight recognized serotypes of AAV based on their respective 
capsid proteins (Smith-Arica 2001; Gao 2002; Lai 2002; Tenenbaum 2003). A A Vl, 2, 
and 3 have approximately 85% amino acid sequence homology to each other, while AAV 
4 and 5 have only 55% homology to AAV2 (Xie 2002). AAVl and 6 are 99% 
homologous and are therefore not considered to be functionally distinct. AAV7 and 8 
have recently been isolated from Rhesus monkeys showing 63-85% amino acid sequence 
identity with the other AAV serotypes (Gao 2002). AAV serotype 2 was the first to be 
isolated and has been the most extensively studied. The recent isolation o f other 
serotypes has expanded the potential utility o f this virus as a gene delivery system. AAV 
has been used as a gene transfer vector in many different cell types, including muscle, 
lung, liver and neurons (Sanlioglu 2001 ; Lai 2002). Alternative serotypes appear to be 
selective for different cell surface markers thus changing the respective transduction 
efficiency between cell types. For example, AAV serotype 2 has been shown to bind 
heparan sulfate proteoglycans (HSPG) using alpha2betaV integrin and fibroblast growth 
factor receptor 1 (FG FRl) as co-receptors (Sanlioglu 2001; Xu 2001; Lai 2002; Pasquale 
2003; Smith 2004). While AAV serotype 4 and 5 bind sialic acid with AAV5 using 
platelet-derived growth factor receptor (PDGFR-alpha polypeptide) as a co-receptor 
(Stover 2000; Walters 2001; Monahan 2002; Xie 2002; Pasquale 2003; Tenenbaum
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2003). Cell specificity between the different serotypes has been well documented. For 
example, AAVl transduces skeletal muscle and retina with high efficiency, while AAV5 
is highly efficient at transducing cells in lung and central nervous tissue (Gao 2002).
Multiple studies have been done in guinea pig cochlea in vivo using low titer 
AAV2 (10^ infectious particles) carrying B-galactosidase or GFP reporter genes (Lalwani 
1996; Lalwani 1997; Lalwani 1998; Kho 2000). The reporter gene product was observed 
in the organ of Corti, spiral ligament, spiral limbus, and spiral ganglion cells. Previous 
studies have suggested that AAV2 is unable to transduce hair cells or support cells in vivo 
and in vitro (Kho 2000; Jero 2001 ; Luebke 2001). Several possible reasons for this are 
the low titers used in the studies ( 10  ̂or 10  ̂ infectious particles) and the use of alternate 
promoters.
Specific Aims
The overall goal o f this project was to explore the utility o f AAV for gene transfer 
in the murine auditory system. Primary cochlear explant cultures represent an attractive 
in vitro model system because the explants maintain intact physiological morphology. 
Much o f the cochlear research currently being done is in guinea pig and chicken models. 
Flowever, we chose to use a murine model to take advantage of the many transgenic 
mutants available that model hearing loss.
The aim o f this project was to identify which AAV serotype (1, 2, or 5) would 
most efficiently transduce hair cells and support cells in vitro. Our primary objectives 
were to: 1) produce high titers o f rAAV virus serotypes 1,2, and 5; 2) establish postnatal 
cochlear explants; 3) transduce explants with AAV-CAG-GFP serotypes 1, 2 or 5 to
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examine overall gene expression; and 4) transduce explants with AAV-GFAP-GFP 
serotypes 1, 2, and 5 to examine support cell specific gene expression.
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Materials and Methods 
Virus production
Adeno-associated virus (AAV) serotypes 1, 2, and 5 were packaged in human 
embryonic kidney 293T cells (ATCC, CRL-11268). Cells were maintained in growth 
medium consisting o f Dulbecco’s modification of Eagle’s medium (DMEM, Cellgro) 
supplemented with 10% fetal bovine serum (FBS, Hyclone), 0.05% penicillin/ 
streptomycin (5000U/mL, Cellgro), 0.1 mM MEM nonessential amino acids (Cellgro), 
ImM MEM sodium pyruvate (Cellgro), and gentamicin (25mg/mL, Cellgro). The day 
before transfection, approximately 1.5x10^ cells were plated on 150mm dishes containing 
growth medium. Twenty-four hours later, medium was changed to DMEM containing 
5% FBS and antibiotics and cells were transfected using Polyfect transfection reagent 
(Qiagen). All plasmids were purified using the Endo-Free Mega kits (Qiagen) or High 
Purity Plasmid Maxiprep kits (Marligen Biosciences). A triple transfection method was 
used with a plasmid ratio of 2:1:1 (Lai 2002). Plasmids used for transfection were: 1) 
pFA6 (containing the required adenoviral helper gene); 2) pRVI (capsid and rep genes for 
serotype 2), pH21 (capsid gene for serotype 1 and rep gene for serotype 2), or pH25a 
(capsid gene for serotype 5 and rep gene for serotype 2); and 3) tram-g^nQ, GFP cassette 
flanked by the AAV ITR’s (Figure 2). These plasmids were obtained from the 
laboratory of Dr. Matthew During Jr. from the University o f Auckland, New Zealand.
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Figure 2. GFP Cassette.
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Figure 2. GFP Cassette.
A schematic representation of the GFP cassettes packaged into the AAV virus. ITR = 
inverted terminal repeats, CAG = chicken beta actin/ Cytomegalovirus hybrid promoter, 
GFAP = glial fibrillary acidic protein promoter, hrGFP = humanized renilla green 
fluorescent protein, WPRE = woodchuck hepatitis post-transcriptional regulatory 
element, and BGH-PA = bovine growth hormone poly-adenylation signal.
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Cells were harvested 48-72 hours later using freeing solution (700mM NaCl, 
13mM KCl, 102mM Na2P04, 3mM Na2EDTA). Cells were pelleted by centrifugation at 
6,000XG for 15 minutes and re-suspended in 150mM NaCl plus 20mM Tris pH 8.0 
(50mL for every 10 X 150mm dishes). Cells were lysed by three freeze-thaw cycles in a 
dry ice-ethanol bath followed by treatment with 5OU benzonase (Novagen) and 0.5% 
sodium deoxycholate. The cell debris was pelleted at 6,000XG for 15 minutes at 4®C. 
The supernatant was then incubated at 56°C for 15 minutes to heat inactivate the 
benzonase. The cell lysate was buffer exchanged with 150mM NaCl plus 20mM Tris pH 
8.0 to remove the deoxycholate and was then condensed to approximately 7.5mL using 
JumboSep centrifugation devices (Pall). The virus was then purified as previously 
described by Zolotukhin et al. (2002). Briefly, discontinuous iodixanol (OptiPrep, 
Accurate Chemical) step gradients were used to displace the less dense cell lysate. Each 
gradient consisted of 5mL o f 60%, 5mL of 40%, 6mL of 25%, and 8mL of 15% 
iodixanol. Iodixanol was diluted with PBS containing ImM MgCb and 2.5mM KCl.
The 15% solution also contained IM NaCl to prevent aggregation of viral particles. 
Sealed gradient tubes (25x89 mm, Beckman) were centrifuged at 65,000XG in a Ti-70 
rotor for 2.5 hour at 18°C. Using an 18-gauge needle, the virus was collected by 
removing approximately 5-7mL just below the 60-40% interface. The purified virus was 
buffer exchanged (3X) with PBS to remove the iodixanol and condensed in JumboSep 
centrifugation device followed by Biomax-100 concentrators (Millipore) to a final 
volume of approximately 100-3 OOpL.
Purified virus was titered using quantitative PCR. Briefly, 25 pL of purified virus 
was treated with 50U o f benzonase (Novagen) at 37°C for 30 min followed by heat
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inactivation at 95°C for 30 min. Proteinase K (lOfig, Promega) was added and the 
mixture incubated at 50°C for 1 hour and heat inactivated at 95°C for 20 min to expose 
packaged single-stranded DNA. Forward primer (TTC CGG GAG TTT CGC TTT C), 
reverse primer (AAG GCA GGC GGC GAT AG) and probe (/5TET/CCT CCC TAT 
TGC CAC GGC GGA/36-TAMRAph/) were designed from the WPRE sequence, an 
element contained in the GFP plasmid. A standard o f the pAM-CAG-hrGFP-WPRE- 
BGH polyA plasmid was diluted to known concentrations. Virus titers (genomic 
particles (gp) per ml) were determined by RT-PCR on an ABI 7700 (Applied 
Biosystems).
Cochlear cultures
Primary cochlear explants were prepared from PO-Pl CD, mice (Charles River). 
The day o f birth was designated post-natal day 0 (PO). All animal procedures were 
performed in strict accordance with NIH Guide for Care and Use of Laboratory Animals 
and were approved by the University o f Montana Institutional Animal Care and Use 
Committee. Cochleas were dissected as described previously (Raz 1999; Mueller 2002). 
Briefly, the cochlea and vestibular region were aseptically dissected away from the skull 
in cold dissection medium composed o f IX HBSS containing 5mM HEPES and 0.6% 
glucose. The vestibular region was pinned down and the bony outer capsule was 
carefully dissected away from the rest o f the cochlea. Since the cochlea exceeds more 
than one turn at PO, the cochlea was cut into 3 pieces and carefully transferred to Mat-tek 
dishes coated with 0.05mg/mL poly-D-Lysine (BD) followed by 3.75% matrigel (BD). 
Culture medium was DMEM supplemented with 10% FBS, N2 (1:100, Invitrogen),
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Penicillin G (1500U/mL, CalBiochem) plus Fungizone (9pg/mL, Calbiochem) or 
Ciprofloxacin (lOji/mL, Cellgro). AAVl-CAG-hrOFF, AAV2-CAG-hrGFP, AAV5- 
CAG-hrGFP, AAVl-GFAP-hrGFP, AAV2-GFAP-hrGFP or AAV5-GFAP-hrGFP was 
added to the media for a final concentration o f 10'°gp per dish at the time of plating. 
Cultures were maintained at 37°C, 5% CO2 for 5 days in a humidified incubator.
Immunocytochemistry 
Hair cells and Support cells
After 5 days, the medium was carefully aspirated and cultures were fixed in cold 
4% paraformaldehyde (PFA) at room temperature for 30 minutes followed by a post-fix 
in ice-cold methanol for 2 minutes at -20°C. To remove residual PFA and methanol, 
cultures were rinsed with PBS ( 3 X 1 5  minutes). Tissue was permeabilized with PBS 
plus 0.5% Triton X (PBS-Tx) for 1 hour at room temperature. Tissue was then blocked 
with 5% normal goat serum (NGS) for 1 hour at room temperature. All 
immunocytochemical reagents were diluted in PBS-Tx unless otherwise noted. 
Antibodies used, their specificity, and dilutions are outlined in table 1.
All primary antibodies were diluted in PBS-Tx containing 1% NGS and were 
incubated overnight at 4°C. Unbound primary antibodies were removed by washing 
tissue with PBS-Tx (3 X 20 minutes). Primary antibodies were detected by incubation 
with secondary Alexa-Fluor 546 (1:2000, Molecular Probes) for 1 hour at room 
temperature. To remove any unbound secondary antibody and to remove residual salts, 
tissues were then washed with PBS-Tx ( 3 X 1 0  minutes), PBS ( 2 X 5  minutes), sterile 
water, and then mounted using Fluorsave (Calbiochem). Cover slips were sealed with
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clear fingernail polish to prevent dessication. Stained cultures were stored at 4°C in the 
dark.
Stereocillia
After 5 days, cultures were fixed in cold 4% PFA at room temperature for 30 
minutes. To remove any residual PFA, tissue was rinsed with PBS-0.1%Tween 20 (2 
XIO minutes). Phalloidin was diluted in PBS-0.1% Tween 20 and was incubated with the 
tissue for 40 minutes at room temperature. The tissue was then washed with PBS (3X 10 
minutes), once with sterile water, and then mounted using Fluorsave. Cover slips were 
sealed with clear fingernail polish to prevent dessication. Stained cultures were stored at 
4°C in the dark.
Immunocytochemical analysis
Images were taken on Bio-Rad Radiance 2000 MP laser scanning confocal or 
Olympus fluorescence microscopes (model MT-2), magnification ranged from 20X to 
lOOX. Z stack images 1.5-2 microns thick were taken on the confocal microscope.
Images were merged and analyzed using MetaMorph software (Universal Imaging). 
Positive identification of transduced cells was determined by green GFP fluorescence at 
488nm. The specific cell types were identified by red immunofluorescence at 543nm. 
Cell counts were expressed as a ratio of red immunolabel and green GFP expression over 
the cell specific red-immunolabel. A dual label was defined as a positive red 
immunolabel and GFP positive cell. Three to four fields, with a total length of 
approximately 250 microns o f apex or base, were counted at 40X magnification.
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Preliminary experiments revealed a difference in transduction between inner and outer 
hair cells, so separate counts were obtained for both. Counts were also obtained for 
apical and basal portions of the cochlea due to the fact that transduction appears to follow 
a basal to apical preference (personal communication with Dr. Matthew Kelley). Data 
were analyzed using ANOVA using Graphpad Instat (Version 3.0a for Macintosh 2001). 
A p value of less than 0.05 was considered statistically significant.
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Table 1. Antibody information
Antibody Cell type Recognizes Stock
Concentration
Working
Dilution
Suppliers
Phalloidin-546 Stereocillia F-actin 6.6 pM 1:1500 Molecular
Probes
Myosin VI Hair cells Myosin VI 1.1 mg/mL 1:1000 Sigma
Connexin 26 Support cells Gap junctions 1 Pg/pL 1:500 Alpha
Diagnosics
GFAP Support cells Glial fibillary acidic 
protein
4.1 g/L 1:500 Chemicon
GLAST Support cells Glutamate/Aspartate
transporter
0.5 pg/pL 1:100 Alpha
Diagnostics
Jagged 1 Support cells Jagged (Notch 
ligand)
2 pg/mL 1:200 Santa Cruz 
Biotech
p75 Support cells Nerve growth factor 
p75
N/A 1:1000 Chemicon
S 100a Support cells SI00 (Ca+ binding 
protein)
45.6 mg/mL 1:200 DAKO
K)
U \
Table 1. Antibody Information.
Antibodies used in this study. Phalloidin is a directly conjugated phallotoxin that binds 
directly to the F-actin o f the stereocillia. All primary antibodies are rabbit polyclonal.
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Results
Immunocytochemical analysis
Phalloidin, a phallotoxin, binds to the F-actin of stereocillia bundles on the tips of 
hair cells (Mueller 2002). Phalloidin was used to assess the overall health of the explants 
and to orient cultures when stained for support cells (Figure 3 A). The inner rows of hair 
cells have “V” shaped bundles. The outer rows, 3 top rows, have more of a “U” shape.
There are four known unconventional myosins (16, V, VI, and Vila) found in the 
sensory epithelia o f the inner ear (Hasson 1997). Myosin 16, VI, and V ila are located in 
the hair cells while myosin V is located in the afferent nerve cells that innervate the hair 
cells. Myosin VI was used to identify hair cells (Figure 3B). Inner hair cells can be seen 
as the bottom, single row of columnar shaped cells. The outer hair cells form 3-4 rows 
adjacent to the inner hair cells and are more spiracle shaped. The round unstained portion 
on the hair cell is the cells’ nuclei.
There are many different support cell antibodies including: Connexin 26, Glial 
fibrillary acidic protein (GFAP), Glutamate/ Aspartate transporter (GLAST), Jagged 1, 
p75, or SlOOa (Table 1). However, most o f these are not very selective in the type of 
support cells they recognize and have been shown to give irregular results. In our culture 
system, the anti-GLAST antibody was the only antibody that gave consistent results. In 
addition, GLAST is only expressed in border and inner phalangeal cells allowing us to 
specifically identify these support cells. GLAST positive cells were found to ring the 
inner hair cells and in a subset o f unidentified round peripheral cells (Figure 3C). The 
long thread-like staining are processes that are projected from the support cell bodies.
The “holes” are where the inner hair cells rest.
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Figure 3. Confocal Images of Cell Specific Immunostaining
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Figure 3. Confocal Images of Cell Specific Immunostaining.
Representative confocal images o f PO-1 expiant cultures immunostained using 
Phalloidin-546, anti-Myosin VI or anti-GLAST antibodies and Alexa-Fluor-546 
secondary. A, Phalloidin-546 stained stereocillia. The three rows of outer hair cells are at 
the top o f the image and the single row o f inner hair cells is immediately below. B, 
Myosin VI stained hair cells. The bottommost row shows the inner hair cells with 2-3 
rows o f outer hair cells immediately above. C, GLAST stained support cells. GLAST is 
specifically expressed only in border and inner phalangeal cells. The “holes” are where 
the inner hair cells are located. Magnification 40X. Scale bar = 10pm.
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AAV transduction of murine hair cells in cochlear explants
Previous studies have concluded that AAV2 does not transduce cochlear hair cells 
because o f the lack of heparin sulfate on the cell surface (Luebke 2001). AAV5 does not 
require heparin sulfate for cell surface attachment. Therefore, we hypothesized that 
AAV5 would transduce hair cells most efficiently. However in our hands, we observed 
that AAV2 and AAV 1 could efficiently transduce both inner and outer hair cells in 
postnatal cultures, while AAV5 does not.
AAV2 transduction leads to robust GFP reporter gene expression in both the inner 
and outer hair cells. Figure 4 shows a representative image of an AAV2-CAG-GFP 
transduced basilar region cochlear explant. Inner hair cells are along the top of the 
culture and the three rows of outer are immediately below. Yellow cells, or co-localized 
cells, expressed both the GFP gene and are myosin VI positive hair cells. Approximately 
61% of outer hair cells and 37% of inner hair cells expressed GFP (Table 2). GFP 
positive cells were found in both the base and apex with a gradient o f expression 
observed from the base to the apex with more GFP positive cells observed in the base 
(Figure 5). In the apex, 43% of outer and 15% of inner hair cells expressed GFP (Table 
2). GFP expression was also observed in several populations of support cells, possibly 
interdental, Hensen, and Dieters’ cells in both the base and apex. This expression of GFP 
in supporting cells also followed the basal to apical gradient.
Like AAV2, AAVl was also able to efficiently transduce both inner and outer 
hair cells (Figure 6). The same basal to apical expression gradient was also observed 
with AAVl (Figure 7). Outer hair cell transduction was observed at approximately 67% 
and 66% in basal and apical regions, respectively. While inner hair cells showed a
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significant decrease in GFP expression from 52% in the base to 17% in the apex (Table 
2). A A V l transduction also resulted in robust GFP expression in several populations of 
support cells in the base and apex, possibly interdental, Hensen, and a few Dieters’ cells. 
These support cells appear to be more peripheral to the hair cells than what is seen 
following AAV2 transduction.
While AAV5 can transduce murine cochlear hair cells, it is a rare and inefficient 
event (Figure 8). Hair cell transduction efficiency was less than 1% in either base or 
apex (Table 2). When GFP expression was observed in hair cells it was not to the 
magnitude of either o f the other two serotypes examined in this study. AAV5 also 
transduced some support cells and neurons within the periphery of the cultures. GFP 
expression was only observed at very low levels in the apex (Figure 9).
AAVl and AAV2 demonstrated similar levels of transduction in the basal and 
apical regions (Table 2). Approximately 45% of inner and 64% outer hair cells were 
transduced in the basilar region following transduction with AAVl or AAV2. Robust 
GFP expression was observed in outer hair cell and to a lesser extent in inner hair cells. 
Both AAVl and AAV2 showed significantly more transduction of IHC at the base than 
in the apex (p<0.001 and p<0.05, respectively). In addition, both AAVl and AAV2 
showed significantly more transduction (p<0.001) in the outer hair cells than the inner 
hair cells in the apex. The only major statistically significant difference between AAVl 
and AAV2 was the percentage of GFP positive OHC transduced in the apex. AAVl 
showed significantly more transduction (p< 0.05) o f OHC in the apex when compared to 
AAV2. These results clearly show that AAVl and AAV2 can transduce murine cochlear 
hair cells and that the CAG promoter is active within these cells.
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Figure 4. CAG Promoter Drives Gene Expression in AAV2 Transduces Basilar Cochlear Hair Cells
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Figure 4. CAG Promoter Drives Gene Expression in AAV2 Transduced Basilar
Cochlear Hair Cells.
Representative confocal images o f AAV2-CAG-GFP transduced PO cochlear explants 
from the basilar region. AAV2-CAG treated cultures show robust GFP expression in 
inner and outer hair cells. GFP expression is also observed in some supporting cells. Top 
three panels show 40X magnification of fluorescent images; GFP (A), merge (B) and 
Myosin VI respectively (C). Lower three panels show lOOX magnification of same 
images o f GFP (D), merge (E) and Myosin VI (F). Scale bars = 25pm for A, B, and C;
5 pm for D, E, and F.
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Figure 5. CAG Promoter Drives Gene Expression in AAV2 Transduced Apical Cochlear Hair Cells
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Figure 5. CAG Promoter Drives Gene Expression in AAV2 Transduced Apical
Cochlear Hair Cells.
Representative confocal images of AAV2-CAG-GFP transduced PO cochlear explants 
from the apical region. AAV2-CAG treated cultures also show GFP expression in inner 
and outer hair cells and some support cells. Top three panels show 40X magnification of 
fluorescent images; GFP (A), merge (B) and Myosin VI respectively (C). Lower three 
panels show lOOX magnification of same images o f GFP (D), merge (E) and Myosin VI 
(F). Scale bars = 25pm for A, B, and C; 5pm for D, E, and F.
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Figure 6. CAG Promoter Drives Gene Expression in AAVl Transduced Basilar Cochlear Hair Cells
Figure 6. CAG Promoter Drives Gene Expression in A A V l Transduced Basilar
Cochlear Hair Cells.
Representative confocal images o f AAVl-CAG-GFP transduced PO cochlear explants 
from the basilar region. AAV 1 -CAG treated cultures show robust GFP expression in 
inner and outer hair cells and subpopulations o f support cells. Top three panels show 40X 
magnification of fluorescent images; GFP (A), merge (B) and Myosin VI respectively 
(C). Lower three panels show lOOX magnification of same images of GFP (D), merge (E) 
and Myosin VI (F). Scale bars = 25pm for A, B, and C; 5pm for D, E, and F.
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Figure 7. CAG Promoter Drives Gene Expression in AAVl Transduced Apical Cochlear Hair Cells
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Figure 7. CAG Promoter Drives Gene Expression in AAVl Transduced Apical
Cochlear Hair Cells.
Representative confocal images of AAVl-CAG-GFP transduced PO cochlear explants 
from the apical region. AAVl-CAG treated cultures show GFP expression in inner and 
outer hair cells and subpopulations of support cells. Top three panels show 40X 
magnification of fluorescent images; GFP (A), merge (B) and Myosin VI respectively 
(C). Lower three panels show lOOX magnification of same images of GFP (D), merge (E) 
and Myosin VI (F). Scale bars = 25pm for A, B, and C; 5pm for D, E, and F.
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Figure 8. AAV5-CAG Transduction in Basilar Cochlear Explants
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Figure 8. AAV5-CAG Transduction in Basilar Cochlear Explants.
Representative confocal images of AAV5-CAG-GFP transduced PO cochlear explants 
from the basilar region. AAV5-CAG treated cultures show sparse GFP expression in only 
a few support cells. Top three panels show 40X magnification of fluorescent images; 
GFP (A), merge (B) and Myosin VI respectively (C). Lower three panels show lOOX 
magnification of same images of GFP (D), merge (E) and Myosin VI (F). Scale bars = 
25gm for A, B, and C; 5pm for D, E, and F.
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Figure 9. AAV5-CAG Transduction in Apical Cochlear Explants
Figure 9. AAV5-CAG Transduction in Apical Cochlear Explants.
Representative confocal images of AAV5-CAG-GFP transduced PO cochlear explants 
from the apical region. AAV5-CAG treated cultures shows little to no GFP expression in 
hair cells and support cells. Top three panels show 40X magnification of fluorescent 
images; GFP (A), merge (B) and Myosin VI respectively (C). Lower three panels show 
lOOX magnification of same images o f GFP (D), merge (E) and Myosin VI (F). Scale 
bars = 25pm for A, B, and C; 5pm for D, E, and F.
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Table 2. Percentage o f Transduced Hair Cells
Transduced IHC Transduced Transduced Transduced
Base OHC Base IHC Apex OHC Apex
A A V l
CAG 52.14 ± 7 .5  (7) 67.57 ±6.17(7) 17.50 ±7.14  (4) 66.75 ±3.71(4)
GFAP 0 ± 0 (4) 0 ± 09(4) 0 ± 0 ( 3 ) 0 ± 0(3)
AAV2
CAG 37.40 ±4.65 (5) 61.40 ± 5.54(5) 15.50 ±5.23 (6) 43.83 ±8.48(6)
GFAP 0 ± 0 ( 3 ) 0 ± 0(3) 0 ± 0 (6) 0 ± 0(6)
AAV5
CAG 0 ± 0 ( 5 ) 0.60 ± 0.6 (5) 0.40 ± 0.43 (7) 0.80 ± 0.44(7)
GFAP 0 ± 0 (2) 0 ± 0 (2) 0 ± 0 (4) 0 ± 0(4)
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Table 2. Percentage of Transduced Hair Cells.
The percentage o f transduced hair cells ± standard error mean (SEM) is shown. Each 
AAV serotype and promoter is listed in the leftmost column. N values, in parentheses, are 
given for each treatment group for both basal and apical regions. Averages were 
determined as a ratio o f Myosin VI red hair cells and GFP positive labeled cells over 
single Myosin VI labeled hair cells. N = number o f images analyzed, IHC = inner hair 
cells, OHC = outer hair cells, CAG = chicken beta actin/ cytomegalovirus promoter, 
GFAP = glial fibrillary acidic protein promoter.
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AAV transduction of murine support cells in cochlear explants
To assess the transduction o f support cells within murine cochlear explants, we 
created another GFP construct in which the CAG promoter was replaced with the GFAP 
promoter. We chose this promoter based on a report by Rio et al. (2002) which indicated 
that GFAP was expressed in all support cell populations immediately surrounding hair 
cells in mice. Robust transduction o f support cells were observed with both AAVl and 
AAV2, but not with AAV5.
Unfortunately, the lack of a good support cell marker prevented us from 
identifying and quantifying the specific support cell populations transduced. We 
therefore used the myosin VI staining to orient the cultures as well as examine GFP 
expression in hair cells with this promoter. No hair cell expression was observed with 
any serotype using the GFAP promoter. However, a distinctly different distribution of 
GFP expression within the support cells was observed depending on the serotype used.
Based on location relative to hair cells, robust GFP expression is seen in what 
appeared to be Dieters’, interdental and pillar cells following transduction with AAV2 
(Figure 10). High magnification of AAV2 -GFAP transduced cochleas, show GFP 
expression is not in hair cells obvious by the void in the shape of the hair cells (Figure 
lOD and E). In contrast, a very robust GFP expression was only observed in what 
appeared to be Hensen, interdental cells and a few Dieters’ cells following transduction 
with AAVl (Figure 11). Transduction with AAV5 showed GFP expression in peripheral 
support cells, possibly Hensen and a few interdental cells (Figure 12). A similar basal to 
apical gradient that was observed in the GFP expression in hair cells was also seen in the 
GFP expression within support cells following transduction with all serotypes (data not
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shown).
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FigureJQ. GFAP Promoter Drives Gene Expression in AAV2 Transduced Basilar Cochlear Support Cells
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Figure 10. GFAP Promoter Drives Gene Expression in AAV2 Transduced Basilar
Cochlear Support Cells.
Representative confocal images o f AAV2-GFAP-GFP transduced PO cochlear explants 
from the basilar region. AAV2-GFAP treated cochleas show GFP expression in almost 
all types o f supporting cells surrounding the hair cells including interdental (I), Dieters’ 
(D), and pillar or inner phalangeal (*) cells. Top three panels show 40X magnification of 
fluorescent images; GFP (A), merge (B) and Myosin VI respectively (C). Lower three 
panels show lOOX magnification of same images of GFP (D), merge (E) and Myosin VI 
(F). Scale bars = 25pm for A, B, and C; 5pm for D, E, and F.
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GFAP Promoter Drives Gene Expression in AAVl Transduced Basilar Cochlear Su ort Cells
Figure IL  GFAP Promoter Drives Gene Expression in AAVl Transduced Basilar
Cochlear Support Cells.
Representative confocal images o f AAVl-GFAP-GFP transduced PO cochlear explants 
from the basilar region. AAVl-GFAP treated cochleas show robust GFP expression in 
interdental (I), Hensen (H) and few Dieters’ cells. Top three panels show 40X 
magnification of fluorescent images; GFP (A), merge (B) and Myosin VI respectively 
(C). Lower three panels show lOOX magnification of same images of GFP (D), merge (E) 
and Myosin VI (F). Scale bars = 25pm for A, B, and C; 5pm for D, E, and F.
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Figure 12. GFAP Promoter Drives Gene Expression in AAV5 Transduced Basilar Cochlear Support Cells
Figure 12. GFAP Promoter Drives Gene Expression in AAV5 Transduced Basilar
Cochlear Support Cells.
Representative confocal images of AAV5-GFAP-GFP transduced PO cochlear explants 
from the basilar region. AAV5-GFAP treated cochleas show expression in a limited sub­
population o f peripheral support cells, possibly Hensen (H) and interdental (I) cells. Top 
three panels show 40X magnification of fluorescent images; GFP (A), merge (B) and 
Myosin VI respectively (C). Lower three panels show lOOX magnification of same 
images o f GFP (D), merge (E) and Myosin VI (F). Scale bars = 25 pm for A, B, and C;
5 pm for D, E, and F.
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GFP expression within GLAST positive cells
As previously stated, we were unable to specifically identify which support cells 
were transduced by AAV 1, 2, and 5 using a cell specific stain. All conclusions of types 
of supporting cells are based on proximity to hair cells and basic morphology. Anti- 
GLAST antibody specifically labels only inner phalangeal and border cells that 
immediately surround the inner hair cells (Furness 2003; Jin 2003; Rebillard 2003). This 
was the only support cell antibody that gave us consistent and reliable results.
Using GLAST immunostaining, we observed no co-localization of GLAST 
positive cells and GFP expression with neither AAVl nor AAV5 using the CAG or 
GFAP promoter (data not shown). This suggests that AAVl and AAV5 do not 
transduce inner phalangeal cells and border cells. However, AAV2 appears to be able to 
transduce these cell types. Figure 13 shows a representative image of the basilar region 
o f a cochlear explant transduced with AAV2-GFAP-GFP. The GFP expression appears 
to be localized in the cell bodies but not within the extended processes. Robust GFP 
expression was also observed in what appears to be the interdental cells flanking the inner 
hair cell region. The apical region shows decreased transduction with little to no dual 
labeling (Data not shown). Other populations o f transduced support cells are also 
visible.
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Figure 13. Anti-GLAST Staining of AAV2-GFAP-GFP Transduced Basilar Cochlear Explants
Figure 13. Anti-GLAST Staining of AAV2-GFAP Transduced Basilar Cochlear
Explants.
Representative confocal images o f AAV2-GFAP-GFP transduced PO cochlear explants 
stained with anti-GLAST antibody. Anti-GLAST stains only border and inner phalangeal 
cells. The “holes” between the GLAST positive cells are hair cells. Dual positive anti- 
GLAST staining and GFP expression is observed within the cell bodies but not the 
extended processes. Top three panels show 40X magnification of fluorescent images;
GFP (A), merge (B) and GLAST respectively (C). Lower three panels show lOOX 
magnification of same images of GFP (D), merge (E) and GLAST (F). Scale bars = 25 pm 
for A, B, and C; 5pm for D, E, and F.
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Discussion/Conclusions
In previous studies, AAV was shown not to transduce hair cell and support cells 
within the cochlea (Lalwani 1996; Lalwani 1997; Kho 2000; Luebke 2001; Li Duan 
2002). AAV2 was the only serotype used in these studies. The overall conclusion was 
that the cell surface receptor, HSPG, was not present, therefore no transduction could 
occur (Luebke 2001). However, in our study we have shown that AAV2 and AAVl 
carrying the CAG-GFP expression cassette can efficiently transduce murine hair cells in 
vitro. AAVl appears to be the most efficient at transducing hair cells in the apex. The 
primary cell surface receptor for AAVl has not yet been identified. Surprisingly, AAV5 
which binds sialic acid, does not transduce hair cells even though sialic acid is thought to 
be present on hair cells (Tachibana 1990). Further studies are needed to determine the 
transduction efficiency of the remaining AAV serotypes (3, 4, 7, and 8) in the cochlea. 
These serotypes may, or may not, show a more selective tropism based on their cell 
surface receptors. HSPG and sialic acid may only serve to facilitate the initial contact 
between virus and cell, thus enhancing the efficiency of transduction. This may be 
overcome with the use of higher titers.
In addition, the difference in the ability of AAV to transduce these cells and for 
cells to express the transgene could be due to the different titers used in earlier 
experiments. Most o f the previous studies used low titer ( 10̂  or 10  ̂ infectious particles) 
virus, whereas in this study we used a relatively higher titer (10*^ gp). Our study clearly 
demonstrates that AAV can transduce cells within the cochlea at this titer. Notably, we 
did observe a decreased and inconsistent transduction of hair cells with AAVl-CAG 
when lower titers (10^ gp) were used. Interestingly, a very high titer (lO'^ gp) did not
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change the transduction efficiency of AAV5-CAG (data not shown). This suggests that 
titer was not the only factor for efficiency o f AAV5 within the cochlea. Therefore, titer 
can affect the efficiency of AAV transduction but there appears to be a threshold as well 
as other determining factors.
The promoters and enhancer sequences used in the current study are another 
major difference that needs to be considered when comparing our results to previous 
studies. Xu et al. (2001) compared AAV mediated expression of coagulation protein 
human factor X driven by the CAG, CMV, or elongation factor 1 alpha (E F la) 
promoters. That study concluded that the CAG promoter resulted in 9.5-fold higher 
expression than CMV promoter alone and 137-fold higher than E F -la  promoter alone 
(Xu 2001). The majority of previous cochlear AAV studies relied upon the CMV 
promoter (Lalwani 1997; Lalwani 1998; Luebke 2001; Li Duan 2002). These 
experiments resulted in expression in the spiral ligament, spiral ganglion, spiral limbus, 
and within the organ of Corti. However, the cell types within the organ of Corti were not 
specified. Poulsen et al. (2002) compared the transduction of AAV2 and AAV5 in the 
spinal cord using the neuron specific enolase (NSE) and GFAP promoters. This study 
found that high titers of AAV2 and AAV5 transduced similar levels of neurons when the 
NSE promoter was used to drive GFP expression. However, using the GFAP promoter to 
drive GFP expression, AAV5 showed more transduction of astrocytes compared to 
AAV2. Luebke et al. (2001) studied AAV transduction using the CBA, CMV, NSE, 
platelet derived growth factor (PDGF), and E F -la  promoters to drive expression in the 
guinea pig cochlea. That study showed that AAV did not transduce hair cells, but it did 
transduce support cells (Luebke 2001). Furthermore, the support cell expression was
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promoter dependent, thus supporting observations in the current study. The NSE 
promoter drove expression in nerve fibers while E F la  drove expression in the non­
interdental cells o f the spiral limbus. Interestingly, the CBA and CMV promoters did not 
drive expression in any cochlear tissue except cochlear blood vessels. This is very 
interesting considering the CAG promoter used in our study is a hybrid of the CBA and 
CMV promoters. Using the CAG promoter and WPRE element, we observed GFP 
expression in several different types of cells within the cochlea following AAV 
transduction.
Recently, Rio et al. (2002) examined GFAP expression in cochlear cells. Using 
anti-GFAP immunostaining and transgenic mice expressing a reporter gene under control 
of the GFAP promoter, the authors demonstrated a distinct localization o f GFAP in the 
support cells directly associated with the hair cells but not within the hair cells 
themselves. Due to the type of image analysis and lack of a good support cell specific 
antibody, it was not clear exactly which support cell types express GFAP. However, the 
results state that all supporting cells surrounding hair cells express GFAP even though the 
magnification used made it difficult to distinguish between the inner phalangeal and inner 
pillar cells. Figure 14 shows a transmission electron micrograph image of an inner hair 
cell (Furness 2003). This previous study used immunogold staining along with TEM 
microscopy to identify GLAST expression in the cochlea. In this figure, the boundaries 
o f the border cell, inner phalangeal cell, and the inner pillar cell surrounding the inner 
hair cell are clearly visible. Thus, it seems reasonable that using the GLAST promoter 
AAV2 transduction could lead to transgene expression in only the border and inner 
phalangeal cells.
59
Figure 14. Transmission Electron Micrographs of Immunogold Labeling for GLAST
Around Inner Hair Cells of Guinea Pig Cochlea.
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Figure 14. Transmission Electron Micrographs of Immunogold Labeling for GLAST
Around Inner Hair Cells of Guinea Pig Cochlea.
A, Inner hair cell (IHC) flanked on both sides by support cells; inner phalangeal cells 
(IPhC), Pillar cell (PC), border cell (BC). (B and C), are higher power images of outlined 
boxes in A. B, Labeling o f GLAST (arrow heads) is primarily confined to cell membrane. 
C, GLAST is confined to the membrane of inner phalangeal cells as well (arrow heads).
A greater number of particles can be seen in the inner phalangeal cell. Copyright 2003 by 
Society for Neuroscience.
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Cell specific expression will be important for future gene delivery studies and 
clinical trials. Targeting only the cells or tissue of interest will allow for gene expression 
only where it is needed. As shown with the GFAP promoter, specific cells can be 
targeted using AAV. While AAVl-GFAP and AAV2-GFAP have both been shown to 
transduced support cells, AAVl shows a more limited cellular tropism. This data along 
with the previous studies suggests that AAV can be targeted to drive expression in 
specific cell types based on the promoter selected. This is important when only certain 
populations of cells are o f interest. The Myo7A promoter has recently been cloned and 
could be used for gene expression specifically within hair cells (Boeda 2001). The 
introduction o f otoprotective genes directly to the hair cells could increase survival after 
ototoxic or sound damage.
Following transduction with AAV, a pattern of decreasing GFP expression was 
observed in a basal to apical gradient. This gradient is not only seen in the frequency of 
sound transduced by the cochlea but with endogenous gene expression as well (Rio 
2002). Sensitivity to damage (ototoxic or noise related) also follows the same gradient.
It has been speculated in several in vivo gene transfer studies that the region for high 
transduction in the base versus the apex was due to mode of delivery and dissemination 
o f virus (Lalwani 1997; Stover 2000; Li Duan 2002). In vivo studies rely on direct 
injection o f the virus to the cochlea via two main routes. The site of inoculation can 
either be by direct injection into the round window or pumped into the basal portion of 
the scala tympani via cochleostomy (Lalwani 1997; Stover 2000; Li Duan 2002). Thus, 
the conclusion made for the in vivo studies may be valid but the basal to apical gradient 
should also be considered. In this study, both regions were treated with the same titer and
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duration o f virus and the gradient was still observed. In all viral treatment groups, less 
GFP was expressed in the apex versus the base.
Future Studies
This in vitro project is a first step in using AAV as a gene delivery vector in the 
murine auditory system. The next logical step will be to use the AAV serotype(s) found 
to transduce the explants in an in vivo model. Once an efficient mode o f delivery to the 
scala media is established for the mouse, AAV can be used to introduce functional genes 
into the cochlea. These could include developmental genes such as the Math-1, Math-1 
is a developmental transcription factor that is required for hair cell development (Zuo 
2002; Kawamoto 2003). Using adenoviral vectors, Kawamoto et al. (2003) successfully 
introduced the functional M athl gene into guinea pig cochlea. Math-1 positive cells were 
found in non-sensory epithelia within the organ of Corti and within Hensen cells, inner 
sulcus, and interdental cells. Furthermore, over-expression of the Math-1 gene lead to 
immature hair cells in the organ o f Corti and non-sensory epithelia (Kawamoto 2003). 
Other neuroprotective genes could also be introduced including glial derived 
neurotrophic factor (GDNF) or neurotrophic factor 3 (NT3) (Li Duan 2002). These genes 
have been shown to increase survival o f neurons after hair cell damage due to ototoxic 
drugs or noise (Kawamoto 2001; Kanzaki 2002). This type of gene transfer in 
combination with cochlear implants could help preserve the neurons that would 
ultimately deteriorate after hair cell loss and thus increase the chance of restoring hearing.
Adeno-associated viral vectors appear to be promising viral vectors for gene 
therapy in the inner ear. It is important that the remaining AAV serotypes be tested in the
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inner ear to evaluate their transduction ability. Using AAVl and AAV2, the CAG 
promoter was shown to drive expression in many cell types while the GFAP promoter 
was able to drive expression in only supporting cells. Our study has therefore shown that 
AAV can be used to efficiently transduce cells within the murine cochlea in vitro.
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